Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. It develops Sevuparin, a lipopolysaccharide in Phase IIa trial to treat patients with sepsis, septic shock, anemia associated with chronic kidney disease, endotoxemia, severe malaria, and other diseases involving severe systemic inflammation. Modus Therapeutics Holding AB (pu… Read more
Modus Therapeutics Holding AB (MODTX) - Net Assets
Latest net assets as of December 2025: Skr9.07 Million SEK
Based on the latest financial reports, Modus Therapeutics Holding AB (MODTX) has net assets worth Skr9.07 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr12.69 Million) and total liabilities (Skr3.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr9.07 Million |
| % of Total Assets | 71.5% |
| Annual Growth Rate | -12.92% |
| 5-Year Change | -42.35% |
| 10-Year Change | N/A |
| Growth Volatility | 173.76 |
Modus Therapeutics Holding AB - Net Assets Trend (2018–2025)
This chart illustrates how Modus Therapeutics Holding AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Modus Therapeutics Holding AB (2018–2025)
The table below shows the annual net assets of Modus Therapeutics Holding AB from 2018 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr9.07 Million | +324.47% |
| 2024-12-31 | Skr2.14 Million | -87.91% |
| 2023-12-31 | Skr17.68 Million | +784.02% |
| 2022-12-31 | Skr-2.58 Million | -116.43% |
| 2021-12-31 | Skr15.73 Million | +124.95% |
| 2020-12-31 | Skr7.00 Million | +360.42% |
| 2019-12-31 | Skr-2.69 Million | -111.24% |
| 2018-12-31 | Skr23.90 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Modus Therapeutics Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 35146200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr7.30 Million | 80.45% |
| Other Components | Skr353.24 Million | 3894.11% |
| Total Equity | Skr9.07 Million | 100.00% |
Modus Therapeutics Holding AB Competitors by Market Cap
The table below lists competitors of Modus Therapeutics Holding AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AMEDISYS
BE:ADY
|
$860.52K |
|
Solis Minerals Ltd
PINK:SLMFF
|
$861.16K |
|
Asia Pptys Inc
PINK:ASPZ
|
$861.26K |
|
KIMBERLY-CLARK
BE:KMY
|
$861.93K |
|
Exro Technologies Inc
OTCQB:EXROF
|
$859.20K |
|
Silicon Gaming Inc
PINK:SGIC
|
$858.28K |
|
Flexituff Ventures International Limited
NSE:FLEXITUFF
|
$857.31K |
|
UNITED PARCEL SVC-B - Dusseldorf Stock Exchang
DU:UPAB
|
$857.18K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Modus Therapeutics Holding AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,137,000 to 9,071,000, a change of 6,934,000 (324.5%).
- Net loss of 18,543,000 reduced equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 25,478,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-18.54 Million | -204.42% |
| Other Comprehensive Income | Skr-1.00K | -0.01% |
| Other Changes | Skr25.48 Million | +280.87% |
| Total Change | Skr- | 324.47% |
Book Value vs Market Value Analysis
This analysis compares Modus Therapeutics Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.94x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has increased from 0.19x to 1.94x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | Skr1.48 | Skr0.28 | x |
| 2019-12-31 | Skr-0.17 | Skr0.28 | x |
| 2020-12-31 | Skr0.43 | Skr0.28 | x |
| 2021-12-31 | Skr1.27 | Skr0.28 | x |
| 2022-12-31 | Skr-0.16 | Skr0.28 | x |
| 2023-12-31 | Skr1.00 | Skr0.28 | x |
| 2024-12-31 | Skr0.06 | Skr0.28 | x |
| 2025-12-31 | Skr0.14 | Skr0.28 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Modus Therapeutics Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -204.42%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.40x
- Recent ROE (-204.42%) is below the historical average (-182.29%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | -207.73% | 0.00% | 0.00x | 1.96x | Skr-52.04 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-43.31 Million |
| 2020 | -86.05% | 0.00% | 0.00x | 1.07x | Skr-6.72 Million |
| 2021 | -131.50% | 0.00% | 0.00x | 1.35x | Skr-22.27 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-18.06 Million |
| 2023 | -101.22% | 0.00% | 0.00x | 1.13x | Skr-19.67 Million |
| 2024 | -727.42% | 0.00% | 0.00x | 2.29x | Skr-15.76 Million |
| 2025 | -204.42% | 0.00% | 0.00x | 1.40x | Skr-19.45 Million |
Industry Comparison
This section compares Modus Therapeutics Holding AB's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Modus Therapeutics Holding AB (MODTX) | Skr9.07 Million | -207.73% | 0.40x | $859.70K |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |